Orchid Pharma share price
You have to be logged in to add this to Watchlist.- ₹715.00(-1.00%)June 13, 2025 15:29:47 PM IST
- NSE
- BSE
- Vol : 115.12K (NSE + BSE)Last 20 day avg : 289.31 K
Orchid Pharma is trading -1.00% lower at Rs 715.00 as compared to its last closing price. Orchid Pharma has been trading in the price range of 717.55 & 701.35. Orchid Pharma has given -60.48% in this year & -0.56% in the last 5 days. Orchid Pharma has TTM P/E ratio 39.48 as compared to the sector P/E of 25.02.There are 3 analysts who have initiated coverage on Orchid Pharma. There are 2 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 22.29 Crores in its last quarter.Listed peers of Orchid Pharma include Rpg Life Sciences (4.07%), Gufic Biosciences (-0.07%), Orchid Pharma (-1.00%).The Mutual Fund holding in Orchid Pharma was at 18.79% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Orchid Pharma was at 2.69% in 31 Mar 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Jun 15, 2025, 11:41 AM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BIn line with historical values2.86The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values36.32Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility3.09Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.14The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 9.39% from Rs 237.48 crore to Rs 217.10 crore, year-on-year
The company's profit declined by 33.50% year-on-year during the March quarter, dropping from Rs 33.53 crore to Rs 22.29 crore- The debt to equity of the company is higher than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 723.93
- R2
- 817.07
- R3
- 877.13
- S1
- 570.73
- S2
- 510.67
- S3
- 417.53
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Rpg Life Sciences | Bullish | 2,339.50 | 4.07 | 3,881.47 | 32.75 | 7.3 | 0.68 | - |
| Gufic Biosciences | Moderately Bearish | 372.45 | -0.07 | 3,736.34 | 53.33 | 6.18 | 0.03 | 24.97 |
| Orchid Pharma | Neutral | 715.00 | -1.00 | 3,634.72 | 36.34 | 2.86 | - | 10.39 |
| Advanced Enzyme Technologies | Moderately Bullish | 320.30 | -1.48 | 3,576.96 | 27.38 | 2.52 | 1.62 | 1.47 |
| Morepen Laboratories | Neutral | 64.56 | -2.20 | 3,537.59 | 29.40 | 3.06 | - | 3.39 |
- Promoter(s) holds a high stake in the company at 69.84%
- FIIs are invested in this company
- FIIs holding has increased by 0.16 percentage points from previous quarter
- Mutual Funds holding has increased by 1.33 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-26 | Audited Results |
| 2025-02-12 | Quarterly Results |
| 2024-11-11 | Quarterly Results |
| 2024-08-12 | Quarterly Results |
| 2024-05-23 | Audited Results |
- IndustryBiotechnology & Drugs
- ISININE191A01027
- BSE Code524372
- NSE CodeORCHPHARMA
Orchid Pharma is trading at 715.00 as on Fri Jun 13 2025 09:59:47. This is -1.00% lower as compared to its previous closing price of 722.20.
The market capitalization of Orchid Pharma is 3634.72 Cr as on Fri Jun 13 2025 09:59:47.
The average broker rating on Orchid Pharma is Strong Buy. The breakup of analyst rating is given below -
- 2 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Orchid Pharma is 1998.00 whereas the 52 wk low is 603.80
Orchid Pharma can be analyzed on the following key metrics -
- TTM P/E: 39.48
- Sector P/E: 25.02
- Dividend Yield: 0.00%
- D/E ratio: 0.14
Orchid Pharma reported a net profit of 99.66 Cr in 2025.
The Mutual Fund Shareholding was 18.79% at the end of 31 Mar 2025.